Antimicrobial Agents: Types, Mechanisms, and Clinical Uses

Antimicrobial agents are medications and biologic products used to prevent, control, or eliminate infections caused by microorganisms. These microorganisms may include bacteria, viruses, fungi, mycobacteria, protozoa, and opportunistic pathogens.

In respiratory care, antimicrobial agents are especially important because infections can affect the airways, lung tissue, pleural space, and patients with weakened immune defenses.

Proper use requires more than simply choosing a drug. It involves identifying the likely organism, understanding the patient’s condition, selecting the correct route of administration, and monitoring for improvement, adverse effects, and resistance.

What Are Antimicrobial Agents?

Antimicrobial agents are natural or synthetic substances that inhibit the growth of microorganisms or kill them directly. Some were originally developed from naturally occurring compounds, while others were created synthetically or by modifying older medications. These agents are widely used throughout health care because infections remain a major cause of illness, hospitalization, and death.

The term “antimicrobial” is broad. It includes several categories of anti-infective therapy, such as:

• Antibacterial agents for bacterial infections
• Antiviral agents for viral infections
• Antifungal agents for fungal infections
• Antimycobacterial agents for tuberculosis and related infections
• Antiprotozoal agents for certain parasitic infections
• Preventive biologic products such as selected vaccines or monoclonal antibodies

The term “antibiotic” is often used in everyday language to refer to medications that treat infections, but it most accurately refers to antibacterial drugs. Antibiotics do not treat uncomplicated viral infections, such as most cases of acute bronchitis or the common cold. This distinction is important because inappropriate antibacterial use can expose patients to unnecessary side effects and contribute to antimicrobial resistance.

Why Antimicrobial Agents Matter in Respiratory Care

Respiratory infections are common and can range from mild upper airway infections to severe pneumonia with respiratory failure. Antimicrobial agents may be used in conditions such as community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, cystic fibrosis infections, tuberculosis, fungal lung disease, influenza, respiratory syncytial virus, and infections in immunocompromised patients.

The respiratory system has several natural defenses that help prevent infection. These include cough, mucociliary clearance, airway branching, epithelial barriers, antimicrobial peptides, surfactant proteins, alveolar macrophages, and local immune responses. When these defenses work well, the body may eliminate pathogens before infection becomes established.

However, these defenses can fail or become overwhelmed. Patients with airway obstruction, bronchiectasis, diabetes, chronic lung disease, endotracheal intubation, immune-altering diseases, corticosteroid use, cancer therapy, transplantation, or advanced illness may be less able to control infection. In these cases, antimicrobial therapy can be essential, but it still works best when supported by the patient’s immune system, respiratory care, infection control, and careful clinical monitoring.

Principles of Antimicrobial Therapy

The proper use of antimicrobial agents begins with identifying the likely cause of infection. Treatment should be based on the organism involved, the site of infection, the severity of illness, the patient’s risk factors, and the likelihood of drug resistance.

Identify the Likely Organism

Before antimicrobial therapy is started, appropriate diagnostic specimens should be collected when possible. These may include sputum, blood, urine, cerebrospinal fluid, pleural fluid, synovial fluid, peritoneal fluid, stool, or samples obtained through bronchoscopy.

In respiratory care, sputum evaluation is especially important. A sputum Gram stain can provide early information about whether bacteria are present and whether they appear gram-positive or gram-negative. This helps guide initial therapy while culture and susceptibility results are pending.

Common respiratory pathogens may include:

• Streptococcus pneumoniae
• Staphylococcus aureus
• Haemophilus influenzae
• Moraxella catarrhalis
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Mycoplasma pneumoniae
• Chlamydophila pneumoniae
• Legionella pneumophila
• Mycobacterium tuberculosis
• Influenza viruses
• Respiratory syncytial virus
• Aspergillus species
• Pneumocystis jiroveci

Note: The likely organism depends heavily on the clinical setting. Community-acquired infections often involve different pathogens than hospital-acquired or ventilator-associated infections. Patients with cystic fibrosis, neutropenia, or severe immune compromise may have additional risks that influence drug selection.

Start Empiric Therapy When Needed

Culture and susceptibility results often require 24 to 72 hours. For serious infections, clinicians may need to begin treatment before the exact organism is known. This is called empiric therapy.

Empiric therapy is based on the patient’s symptoms, severity of illness, infection site, likely pathogens, recent antimicrobial exposure, local resistance patterns, and clinical guidelines. For example, initial therapy for severe community-acquired pneumonia may need to cover both typical bacteria such as pneumococcus and atypical organisms such as Legionella.

In hospital-acquired pneumonia or ventilator-associated pneumonia, empiric therapy may need broader coverage because resistant gram-negative organisms and methicillin-resistant Staphylococcus aureus may be involved. If risk factors for Pseudomonas aeruginosa are present, antipseudomonal therapy may be needed until culture results provide more specific direction.

Narrow Therapy When Results Are Available

Once the causative organism is identified and susceptibility testing is available, therapy should be narrowed when appropriate. This process is often called de-escalation.

The purpose of narrowing therapy is to use the most targeted effective agent. This reduces unnecessary drug exposure, lowers the risk of adverse effects, decreases cost, and helps limit antimicrobial resistance. Broad coverage can be lifesaving early in severe infection, but it should not continue longer than necessary when a narrower option is available.

Culture and Susceptibility Testing

Susceptibility testing helps determine whether a microorganism is likely to respond to a specific antimicrobial agent. This information is critical when resistance is possible or when the patient is not improving as expected.

Gram Stain

The Gram stain is a rapid and commonly used laboratory method. It classifies bacteria based on differences in the bacterial cell wall. Gram-positive bacteria stain violet, while gram-negative bacteria stain pink. This early classification can help guide empiric therapy.

For example, gram-positive organisms are commonly associated with bronchitis and pneumonia, while gram-negative organisms are often more concerning in seriously ill, debilitated, hospitalized, or immunosuppressed patients. However, Gram stain results are only one piece of the overall clinical picture.

Kirby-Bauer Disk Diffusion Test

The Kirby-Bauer disk diffusion test is a common method for susceptibility testing. In this test, disks containing antibiotics are placed on an agar plate inoculated with bacteria. If the organism is susceptible, a clear zone of inhibition forms around the disk.

The size of the zone is compared with established breakpoints to classify the organism as susceptible, intermediate, or resistant. This helps clinicians choose an agent that is likely to work against the organism.

E-Test and Minimal Inhibitory Concentration

The E-test uses a strip containing a gradient of antimicrobial concentration. After incubation, an elliptical zone of inhibition forms. This method can help determine the minimal inhibitory concentration, or MIC.

The MIC is the lowest concentration of an antimicrobial agent that prevents visible bacterial growth. MIC values can guide therapy, especially when treating serious infections, resistant organisms, or infections in difficult-to-penetrate tissues.

Minimal Bactericidal Concentration

The minimal bactericidal concentration, or MBC, is the lowest concentration of an antimicrobial that kills the organism after incubation. While MIC testing is commonly used in clinical practice, MBC testing is not performed routinely in most laboratories. It is more often used in specialized situations or research settings.

Bacteriostatic vs. Bactericidal Agents

Antimicrobial agents may be described as bacteriostatic or bactericidal.

Bacteriostatic agents inhibit bacterial growth but do not directly kill the organism. They depend partly on the patient’s immune system to eliminate the infection. Bactericidal agents kill bacteria directly.

This distinction can matter in severe infections or in patients with impaired immune defenses. A bactericidal drug may be preferred for certain life-threatening infections, bloodstream infections, central nervous system infections, or infections in immunocompromised patients. However, the best choice still depends on the organism, drug activity, infection site, patient factors, and susceptibility results.

Factors That Influence Drug Selection

Successful antimicrobial therapy depends on three major factors: the host, the organism, and the drug.

Host Factors

Host factors are patient-specific details that influence whether a medication is appropriate or safe. These include:

• Allergy history
• Age
• Pregnancy or lactation status
• Immune function
• Kidney function
• Liver function
• Infection site
• Severity of illness
• Recent antimicrobial exposure
• Travel history
• Other diseases
• Current medications
• Ability to take oral medication
• Risk for drug interactions

Note: An immunocompetent patient may recover with standard therapy, while an immunocompromised patient may fail to improve even when the correct drug is chosen. High-risk patients include those with AIDS, cancer chemotherapy exposure, corticosteroid therapy, solid organ transplantation, diabetes, or bone marrow transplantation.

Organism Factors

The organism itself affects treatment decisions. Some microorganisms are naturally resistant to certain drug classes. Others acquire resistance through genetic changes or exposure to antimicrobial pressure.

For example, Pseudomonas aeruginosa may require antipseudomonal agents, while methicillin-resistant Staphylococcus aureus may require drugs such as vancomycin or linezolid. Mycoplasma pneumoniae lacks a typical bacterial cell wall, so drugs that target cell wall synthesis are not effective against it.

Drug Factors

Drug selection also depends on the properties of the medication. Important drug factors include:

• Spectrum of activity
• Route of administration
• Tissue penetration
• Pharmacokinetics and pharmacodynamics
• Dosing frequency
• Toxicity profile
• Cost
• Drug interactions
• Need for monitoring
• Ability to reach the infection site

Note: Some drugs work well in the bloodstream but penetrate poorly into the central nervous system, abscesses, lung tissue, or areas with poor blood supply. Infections involving foreign bodies, catheters, prosthetic devices, or necrotic tissue may not resolve with antimicrobial therapy alone. Removal of infected material may be necessary.

Antimicrobial Resistance

Antimicrobial resistance is one of the most serious challenges in infection management. Resistance occurs when microorganisms develop mechanisms that allow them to survive exposure to drugs that would normally inhibit or kill them.

Resistance may develop through several mechanisms, including:

• Enzymes that destroy or modify antibiotics
• Changes in cell wall or membrane permeability
• Efflux pumps that remove the drug from the cell
• Altered target sites that prevent drug binding
• Biofilm formation on artificial surfaces
• Genetic transfer between organisms

Widespread use of antimicrobials in health care and agriculture increases selective pressure. This allows resistant organisms to emerge and spread. When resistance is present, empiric therapy may fail, and the patient may worsen while awaiting culture results.

Careful antimicrobial use is one of the main ways to reduce this problem. This includes obtaining cultures when possible, using the narrowest effective therapy, avoiding antibiotics for uncomplicated viral infections, using the correct dose and duration, and monitoring clinical response.

Combination Antimicrobial Therapy

Combination therapy means using more than one antimicrobial agent at the same time. It may be appropriate in selected situations.

Combination therapy may be used to:

• Provide broad coverage during empiric treatment
• Treat polymicrobial infections
• Improve coverage in severe infections
• Treat resistant organisms
• Reduce the emergence of resistance in certain diseases
• Produce synergy between drugs

Synergy occurs when the combined effect of two agents is greater than the sum of their individual effects. This can be useful in certain serious infections.

However, not all combinations are beneficial. Some combinations can produce antagonism, where one drug interferes with another and reduces effectiveness. Combination therapy may also increase toxicity, cost, and drug interactions. For this reason, it should be used thoughtfully and adjusted once diagnostic information is available.

Major Classes of Antibacterial Agents

Antibacterial agents work through several major mechanisms. Some inhibit bacterial cell wall synthesis, some interfere with protein synthesis, some disrupt nucleic acid function, and others affect cell membranes or metabolic pathways.

Cell Wall Synthesis Inhibitors

Bacterial cell walls contain peptidoglycan, which helps maintain cell structure. Drugs that inhibit cell wall synthesis weaken the bacteria and may cause cell lysis and death.

Major classes in this group include:

• Penicillins
• Cephalosporins
• Carbapenems
• Monobactams

Penicillins are beta-lactam antibiotics that bind to bacterial cell wall proteins and interfere with peptidoglycan cross-linking. Some penicillins are narrow-spectrum, while others have broader gram-negative activity. Beta-lactamase inhibitor combinations, such as amoxicillin-clavulanate and piperacillin-tazobactam, expand coverage by protecting the beta-lactam drug from enzymatic destruction.

Cephalosporins are also beta-lactam antibiotics and are often classified by generation. Earlier generations generally have stronger gram-positive activity, while later generations often have expanded gram-negative activity. Some cephalosporins are useful in respiratory infections, including pneumonia, depending on the likely pathogens.

Carbapenems are broad-spectrum beta-lactams with activity against many gram-positive, gram-negative, and anaerobic organisms. They are often reserved for serious infections or resistant organisms.

Monobactams, such as aztreonam, have activity mainly against aerobic gram-negative bacteria. Aztreonam is notable because it is less likely to cause allergic reactions in patients with penicillin allergy.

Protein Synthesis Inhibitors

Some antimicrobial agents inhibit bacterial protein synthesis by binding to bacterial ribosomes. This prevents bacteria from producing proteins needed for growth and survival.

Important drug classes include:

• Aminoglycosides
• Macrolides
• Tetracyclines
• Ketolides
• Chloramphenicol
• Clindamycin
• Streptogramins
• Oxazolidinones

Aminoglycosides include gentamicin, tobramycin, and amikacin. These drugs are generally bactericidal and are especially useful against serious gram-negative infections, including Pseudomonas aeruginosa. They require careful monitoring because of potential kidney toxicity and ototoxicity.

Macrolides include erythromycin, clarithromycin, and azithromycin. These agents bind to the 50S ribosomal subunit and are commonly used in respiratory infections. They are useful against atypical organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

Tetracyclines are broad-spectrum agents and may be useful against organisms such as Haemophilus and Mycoplasma. Doxycycline is commonly used in some respiratory infections.

Linezolid belongs to the oxazolidinone class and is active against important gram-positive organisms, including some resistant bacteria.

Nucleic Acid Function Inhibitors

Some antibacterial agents interfere with DNA replication or RNA synthesis. Fluoroquinolones are an important example.

Fluoroquinolones include ciprofloxacin, levofloxacin, and moxifloxacin. Some agents have strong gram-negative activity, while respiratory fluoroquinolones such as levofloxacin and moxifloxacin have activity against organisms commonly associated with pneumonia.

Potential adverse effects include nausea, vomiting, diarrhea, QT interval prolongation, seizures in susceptible patients, and interactions with medications such as warfarin. Absorption can be reduced when taken with antacids or iron supplements. Some fluoroquinolones require renal dosing adjustment.

Other Important Antibacterial Agents

Other antibacterial agents include vancomycin, trimethoprim-sulfamethoxazole, chloramphenicol, clindamycin, and others.

• Vancomycin is commonly used for serious gram-positive infections, including infections caused by methicillin-resistant Staphylococcus aureus.
• Trimethoprim-sulfamethoxazole is important in the treatment of Pneumocystis pneumonia and certain bacterial infections.
• Chloramphenicol has broad activity but is used less often because safer alternatives are usually available. Bone marrow toxicity is a major concern.
• Clindamycin may be used for selected anaerobic and gram-positive infections, depending on susceptibility and clinical setting.

Antimicrobial Agents for Respiratory Infections

Respiratory infections require careful attention to the likely pathogen and clinical setting.

Acute Rhinosinusitis and Bronchitis

Acute community-acquired rhinosinusitis may involve Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or respiratory viruses.

Acute bronchitis is most often viral. Antibiotics are not routinely needed unless a bacterial cause is suspected or the patient has specific risk factors. Organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis may be involved in selected cases.

Exacerbations of chronic bronchitis commonly involve Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Treatment depends on severity, sputum changes, risk factors, and likelihood of bacterial infection.

Community-Acquired Pneumonia

Community-acquired pneumonia is treated based on severity, patient risk factors, and likely pathogens. Common agents may include macrolides such as azithromycin or clarithromycin, doxycycline, beta-lactams such as amoxicillin-clavulanate, or respiratory fluoroquinolones such as levofloxacin or moxifloxacin.

Severe community-acquired pneumonia often requires combination therapy to cover common bacterial pathogens and atypical organisms. If risk factors for Pseudomonas are present, antipseudomonal therapy may be needed.

Hospital-Acquired and Ventilator-Associated Pneumonia

Hospital-acquired pneumonia and ventilator-associated pneumonia require special attention because resistant organisms are more likely. These infections may involve Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, and other nosocomial pathogens.

Local resistance patterns are especially important. The organisms found in one hospital or ICU may differ from those found in another. Empiric therapy must account for local susceptibility data, patient risk factors, and severity of illness.

Possible antipseudomonal agents include cefepime, ceftazidime, piperacillin-tazobactam, or selected carbapenems. These may be combined with an aminoglycoside or fluoroquinolone in certain cases.

Inhaled Antimicrobial Agents

Inhaled antimicrobial agents are important in respiratory care because they deliver medication directly to the airways. This can produce high local concentrations at the infection site while reducing some systemic exposure.

Common inhaled antimicrobial agents include:

• Tobramycin
• Aztreonam
• Colistin
• Pentamidine
• Ribavirin
• Zanamivir

Tobramycin

Tobramycin is an aminoglycoside used against Pseudomonas aeruginosa. In respiratory care, it is strongly associated with cystic fibrosis and chronic Pseudomonas airway infection.

Tobramycin may be given as a nebulized solution or dry powder inhaler. The nebulized form is commonly administered as 300 mg twice daily in 28-day cycles, followed by 28 days off. The dry powder form uses capsules inhaled through a specific device. No other medications should be mixed with tobramycin in the nebulizer.

Potential concerns include bronchospasm, airway irritation, kidney toxicity, and ototoxicity. Although inhaled delivery reduces systemic exposure, monitoring remains important.

Aztreonam

Aztreonam inhalation solution is used for Pseudomonas aeruginosa in cystic fibrosis. It is administered through an approved mesh nebulizer system. Standard therapy often follows a 28-day on and 28-day off cycle.

Because aztreonam can cause bronchospasm or allergic reactions, pulmonary function screening may be performed before treatment. A fast-acting bronchodilator is commonly given before the medication to reduce bronchospasm risk.

Colistin

Colistin, also known as polymyxin E, may be used for refractory gram-negative respiratory infections, including Pseudomonas infections. It may be delivered by nebulizer in selected patients. Its use requires careful attention to drug preparation, delivery device, patient tolerance, and possible toxicity.

Pentamidine

Pentamidine isethionate is used for prophylaxis against Pneumocystis pneumonia in selected immunosuppressed patients. It is administered by small-volume nebulizer, typically using a filtered system with one-way valves and a downstream particle filter.

This is important because aerosolized pentamidine can escape into room air and expose health care workers or nearby patients. Proper equipment and technique reduce environmental contamination and improve safety.

Ribavirin

Ribavirin is an antiviral agent associated with treatment of respiratory syncytial virus, especially severe RSV infection in infants and young children. It is administered only with a small-particle aerosol generator.

The treatment schedule may involve prolonged aerosol delivery over several days. Because ribavirin aerosol has specific safety and delivery concerns, it requires strict adherence to proper equipment use and environmental precautions.

Zanamivir

Zanamivir is an antiviral agent used for influenza treatment or prevention in selected patients. It is delivered by dry powder inhaler. Patients must be able to generate adequate inspiratory flow and use the device correctly.

Because zanamivir is inhaled, respiratory assessment is important, especially in patients with reactive airway disease or a history of bronchospasm.

Antimycobacterial Agents

Antimycobacterial agents are used to treat infections caused by mycobacteria, especially tuberculosis. Pulmonary tuberculosis requires combination therapy because the organism is difficult to eradicate and resistance can develop if therapy is inadequate.

First-line therapy commonly includes:

• Isoniazid
• Rifampin or another rifamycin
• Pyrazinamide
• Ethambutol

Treatment requires a long duration and strong adherence. Incomplete therapy increases the risk of relapse and drug resistance. Monitoring is important because these agents may cause significant adverse effects.

Isoniazid and rifampin can cause liver toxicity. Rifampin can also interact with many medications. Ethambutol may affect vision, especially color discrimination and visual acuity. Pyrazinamide may also contribute to liver toxicity and other adverse effects. Patients receiving tuberculosis therapy need ongoing evaluation for drug tolerance, adherence, and treatment response.

Antifungal Agents

Fungal infections are particularly important in immunocompromised patients. Fungal lung disease may occur in patients with weakened immune defenses, chronic illness, transplantation, neutropenia, or prolonged corticosteroid exposure.

Major antifungal classes include:

• Polyenes
• Azoles
• Echinocandins
• Flucytosine

Polyenes

Amphotericin B is a polyene antifungal that binds to fungal cell membranes. It can be effective in severe fungal infections but may cause significant toxicity, especially kidney toxicity and infusion-related reactions.

Azoles

Azoles include fluconazole, itraconazole, voriconazole, and posaconazole. These agents interfere with fungal cell membrane synthesis. They differ in spectrum, drug interactions, tissue penetration, and toxicity profile.

Azoles may interact with many medications because they affect hepatic enzyme systems. Liver function monitoring may be needed depending on the agent and duration of therapy.

Echinocandins

Echinocandins include caspofungin, micafungin, and anidulafungin. They inhibit fungal cell wall synthesis and are useful for selected fungal infections. Their role depends on the organism, severity of infection, and patient-specific factors.

Antiviral Agents

Antiviral agents are used for viral infections, but they differ from antibacterial agents because viruses rely on host cells for replication. Antiviral drugs often target specific steps in viral replication.

Examples include:

• Acyclovir
• Ganciclovir
• Valganciclovir
• Cidofovir
• Foscarnet
• Oseltamivir
• Zanamivir
• Amantadine
• Rimantadine

In respiratory care, influenza therapy and prevention are especially relevant. Oseltamivir is given orally, while zanamivir is inhaled. These agents may be used when clinically indicated, especially in patients at higher risk for complications.

Antiviral therapy is not the same as antibacterial therapy. Antibiotics do not treat uncomplicated viral infections. However, viral infections can predispose patients to secondary bacterial pneumonia, which may require antibacterial coverage when suspected.

Prevention and Antimicrobial Use

Preventing infection reduces the need for antimicrobial therapy and lowers the opportunity for resistant organisms to emerge. Infection prevention is especially important in hospitals, long-term care facilities, ICUs, and patients with chronic respiratory disease.

Health care-associated infections spread when three elements are present:

• A source of pathogens
• A route of transmission
• A susceptible host

Prevention efforts focus on interrupting this chain. Respiratory therapists and other health care workers help reduce infection risk through hand hygiene, disinfection, isolation precautions, ventilator care practices, proper suctioning technique, equipment cleaning, and appropriate handling of aerosol-generating procedures.

Vaccination is another important prevention strategy. Influenza vaccination is recommended for many patients, especially those at increased risk for severe respiratory illness. Pneumococcal vaccination helps reduce the risk of pneumococcal pneumonia and other serious pneumococcal infections in older adults and high-risk patients.

Palivizumab is a preventive monoclonal antibody used in selected high-risk infants to reduce the risk of severe RSV lower respiratory tract infection. It is not a general treatment for all respiratory symptoms. It is used for specific risk groups and usually given monthly during RSV season.

Cystic Fibrosis and Chronic Airway Infection

Cystic fibrosis is an important example of how antimicrobial therapy fits into a broader respiratory care plan. Patients with cystic fibrosis often develop thick, retained secretions that promote chronic airway infection and inflammation. Pseudomonas aeruginosa is a major pathogen associated with progressive lung disease in these patients.

Treatment is usually structured to improve airway function and medication delivery. A typical sequence may include:

• Supplemental oxygen when needed
• Bronchodilator therapy to reduce airway obstruction
• Mucolytic or mucokinetic therapy to improve secretion clearance
• Airway clearance therapy and directed coughing
• Aerosolized antimicrobial therapy when indicated

Inhaled tobramycin, aztreonam, or colistin may be used when Pseudomonas infection or colonization is confirmed. These medications are not interchangeable. Each has a specific delivery device, dosing pattern, indication, and safety profile.

Response to therapy may be assessed by oxygenation, symptoms, breath sounds, sputum characteristics, spirometry values such as FEV₁, chest imaging, culture results, and overall clinical condition.

Monitoring Response to Therapy

Monitoring is essential after antimicrobial therapy begins. A patient should be assessed for clinical improvement, possible treatment failure, and adverse effects.

Signs of improvement may include:

• Reduced fever
• Improved respiratory symptoms
• Decreased work of breathing
• Improved oxygenation
• Improved white blood cell count
• Less purulent sputum
• Improved radiographic findings
• Negative or improving culture results
• Better overall clinical status

Signs of possible treatment failure may include persistent fever, worsening oxygenation, repeated positive cultures, elevated white blood cell count, worsening symptoms, hypotension, altered mental status, or signs of sepsis.

When treatment failure is suspected, clinicians should consider several possibilities. The organism may be resistant, the diagnosis may be incorrect, drug levels may be inadequate, tissue penetration may be poor, the patient may not be taking the medication correctly, an abscess may be present, or a foreign body may be infected. Noninfectious causes of symptoms should also be considered.

Respiratory Care Assessment

Respiratory therapists play an important role before, during, and after antimicrobial therapy. Assessment helps identify infection, track response, and detect complications.

Before therapy, respiratory care assessment may include:

• Allergy history
• Current symptoms
• Vital signs
• Oxygenation status
• Breath sounds
• Work of breathing
• Sputum color, odor, consistency, and volume
• Culture results
• Radiographic findings
• Current medications
• Risk factors for resistant organisms

During therapy, the therapist monitors respiratory status closely. This includes oxygen requirements, sputum production, airway clearance, ventilator status, breath sounds, and signs of improvement or deterioration.

For aerosolized antimicrobial agents, assessment also includes bronchospasm risk, airway patency, device technique, patient tolerance, environmental safety, and proper cleaning or disposal of equipment.

Safety and Adverse Effects

All antimicrobial agents have potential adverse effects. Some are mild, while others may be serious. The risk depends on the drug, dose, duration, route, patient age, kidney and liver function, immune status, and interacting medications.

Examples include:

• Aminoglycosides may cause kidney toxicity and ototoxicity.
• Vancomycin may require monitoring to reduce toxicity risk.
• Macrolides may cause gastrointestinal effects and drug interactions.
• Fluoroquinolones may cause gastrointestinal symptoms, QT prolongation, central nervous system effects, and drug interactions.
• Rifampin may cause liver toxicity and significant drug interactions.
• Ethambutol may cause visual disturbances.
• Amphotericin B may cause kidney toxicity.
• Azoles may cause liver effects and drug interactions.
• Inhaled agents may cause bronchospasm or airway irritation.

Note: Safe antimicrobial use requires reviewing allergies, kidney and liver function, current medications, pregnancy or lactation status, and prior adverse reactions. In some cases, blood levels or laboratory values must be monitored.

Avoiding Inappropriate Use

Antimicrobial agents should not be used indiscriminately. Inappropriate use can harm patients and contribute to resistance.

Common examples of inappropriate use include giving antibiotics for uncomplicated viral infections, continuing broad-spectrum therapy after culture results support a narrower drug, using the wrong dose or duration, failing to account for kidney or liver function, and using antimicrobial therapy without addressing an infected catheter, abscess, or foreign body.

Good antimicrobial practice includes choosing the right drug for the likely organism, obtaining cultures when appropriate, narrowing therapy when possible, avoiding unnecessary antibiotics, and monitoring the patient’s response.

Antimicrobial Agents Practice Questions

1. What are antimicrobial agents?
Antimicrobial agents are substances or medications that kill microorganisms or inhibit their growth, including bacteria, viruses, fungi, mycobacteria, and other pathogens.

2. What is the main purpose of antimicrobial therapy?
The main purpose of antimicrobial therapy is to prevent, control, or treat infections by targeting the organism responsible for the disease.

3. How are antimicrobial agents different from antibiotics?
Antimicrobial agents include antibiotics, antivirals, antifungals, and other anti-infective drugs, while antibiotics specifically target bacterial infections.

4. Why should diagnostic specimens be collected before antimicrobial therapy when possible?
Specimens should be collected before therapy because antibiotics can reduce the chance of identifying the causative organism in cultures.

5. What types of specimens may be collected to identify an infection?
Specimens may include sputum, blood, urine, cerebrospinal fluid, pleural fluid, synovial fluid, peritoneal fluid, stool, or respiratory samples.

6. Why is sputum testing important in respiratory infections?
Sputum testing helps determine whether bacteria are present and provides early clues about the likely respiratory pathogen.

7. What does a Gram stain help identify?
A Gram stain helps classify bacteria as gram-positive or gram-negative based on differences in the bacterial cell wall.

8. What color do gram-positive bacteria appear on a Gram stain?
Gram-positive bacteria appear violet on a Gram stain.

9. What color do gram-negative bacteria appear on a Gram stain?
Gram-negative bacteria appear pink on a Gram stain.

10. What is empiric antimicrobial therapy?
Empiric antimicrobial therapy is treatment started before the exact organism is known, based on likely pathogens, symptoms, severity, infection site, and resistance patterns.

11. Why is empiric therapy often needed in serious infections?
Empiric therapy is often needed because culture and susceptibility results may take 24 to 72 hours, and delaying treatment can be dangerous in serious infections.

12. What should happen once culture and susceptibility results are available?
Therapy should be narrowed or adjusted to target the specific organism and reduce unnecessary antimicrobial exposure.

13. What is antibiotic de-escalation?
Antibiotic de-escalation is the process of changing from broad antimicrobial coverage to a more targeted medication once the organism and susceptibility pattern are known.

14. Why is antimicrobial de-escalation important?
De-escalation helps improve targeted treatment, reduce side effects, lower costs, and limit antimicrobial resistance.

15. What is susceptibility testing?
Susceptibility testing determines whether a microorganism is likely to respond to a specific antimicrobial agent.

16. What is the Kirby-Bauer disk diffusion test?
The Kirby-Bauer test is a susceptibility method in which antibiotic disks are placed on an agar plate to see whether bacterial growth is inhibited.

17. What does a zone of inhibition represent?
A zone of inhibition is the clear area around an antibiotic disk where bacterial growth has been prevented.

18. What is an E-test used to determine?
An E-test is used to help determine the minimal inhibitory concentration of an antimicrobial agent.

19. What does MIC stand for?
MIC stands for minimal inhibitory concentration.

20. What is the minimal inhibitory concentration?
The minimal inhibitory concentration is the lowest concentration of an antimicrobial agent that prevents visible bacterial growth.

21. What does MBC stand for?
MBC stands for minimal bactericidal concentration.

22. What is the minimal bactericidal concentration?
The minimal bactericidal concentration is the lowest concentration of an antimicrobial agent that kills the organism after incubation.

23. Are MBC tests routinely performed in most clinical laboratories?
No. MBC testing is not routinely performed in most laboratories and is more often used in specialized settings or research.

24. What is a bacteriostatic antimicrobial agent?
A bacteriostatic agent inhibits bacterial growth but does not directly kill the organism.

25. What is a bactericidal antimicrobial agent?
A bactericidal agent kills bacteria directly.

26. What three major factors influence successful antimicrobial therapy?
Successful antimicrobial therapy depends on host factors, organism factors, and drug factors.

27. What are examples of host factors that affect antimicrobial selection?
Host factors include allergy history, age, immune status, kidney function, liver function, pregnancy status, infection site, and current medications.

28. Why does immune function matter during antimicrobial therapy?
Immune function matters because antimicrobial agents often work with the patient’s defenses, and immunocompromised patients may not respond as well even with appropriate therapy.

29. Which patients are at increased risk for poor response to infection?
Patients with AIDS, cancer chemotherapy exposure, corticosteroid therapy, diabetes, solid organ transplantation, or bone marrow transplantation are at increased risk.

30. Why does the infection site affect antimicrobial choice?
The infection site matters because some drugs penetrate certain tissues better than others, which affects whether the medication reaches the organism in adequate concentration.

31. Why may an infection involving a catheter or prosthetic device fail to resolve with medication alone?
Foreign bodies can harbor organisms and biofilm, so removal of the catheter, device, or infected material may be necessary.

32. What drug factors are considered when selecting an antimicrobial agent?
Drug factors include spectrum of activity, route of administration, dosing ease, toxicity, tissue penetration, cost, pharmacologic properties, and drug interactions.

33. What is antimicrobial resistance?
Antimicrobial resistance occurs when microorganisms develop the ability to survive exposure to drugs that would normally inhibit or kill them.

34. How can bacteria destroy or inactivate antimicrobial drugs?
Bacteria can produce enzymes that destroy or modify antibiotics before the drugs can work.

35. How can changes in bacterial permeability cause resistance?
Changes in cell wall or membrane permeability can prevent enough drug from entering the bacterial cell.

36. What are efflux pumps?
Efflux pumps are bacterial mechanisms that remove antimicrobial drugs from the cell, lowering the drug concentration inside the organism.

37. How can altered target sites contribute to resistance?
Altered target sites prevent the antimicrobial agent from binding effectively, reducing or eliminating the drug’s activity.

38. Why does widespread antimicrobial use contribute to resistance?
Widespread use creates selective pressure that allows resistant organisms to survive, multiply, and spread.

39. What is combination antimicrobial therapy?
Combination therapy is the use of more than one antimicrobial agent at the same time to treat or prevent infection.

40. Why might combination therapy be used during empiric treatment?
Combination therapy may be used to provide broad coverage when the exact pathogen is not yet known.

41. What is a polymicrobial infection?
A polymicrobial infection is an infection caused by more than one type of microorganism.

42. What does antimicrobial synergy mean?
Synergy means two antimicrobial agents work together in a way that produces a greater effect than their individual effects added together.

43. What is antimicrobial antagonism?
Antagonism occurs when one antimicrobial agent interferes with the activity of another, reducing the overall effectiveness of therapy.

44. What is the main mechanism of beta-lactam antibiotics?
Beta-lactam antibiotics inhibit bacterial cell wall synthesis, weakening the cell wall and often leading to bacterial death.

45. What antibiotic classes inhibit bacterial cell wall synthesis?
Penicillins, cephalosporins, carbapenems, and monobactams inhibit bacterial cell wall synthesis.

46. How do penicillins work?
Penicillins bind to bacterial cell wall proteins and interfere with peptidoglycan cross-linking, reducing cell wall strength.

47. Why are beta-lactamase inhibitor combinations used?
Beta-lactamase inhibitor combinations protect the beta-lactam antibiotic from enzymatic destruction and expand its coverage.

48. What is an example of a beta-lactamase inhibitor combination?
Examples include amoxicillin-clavulanate and piperacillin-tazobactam.

49. How are cephalosporins commonly classified?
Cephalosporins are commonly classified by generation, with earlier generations generally having more gram-positive activity and later generations having expanded gram-negative activity.

50. Why are carbapenems often reserved for serious infections?
Carbapenems are broad-spectrum agents with activity against many organisms, so they are often reserved for serious infections or resistant pathogens.

51. What is aztreonam?
Aztreonam is a monobactam antibiotic with activity mainly against aerobic gram-negative bacteria.

52. Why is aztreonam notable in patients with penicillin allergy?
Aztreonam is less likely to cause allergic reactions in patients with penicillin allergy compared with many other beta-lactam drugs.

53. What major antimicrobial classes inhibit bacterial protein synthesis?
Protein synthesis inhibitors include aminoglycosides, macrolides, tetracyclines, ketolides, chloramphenicol, clindamycin, streptogramins, and oxazolidinones.

54. What are examples of aminoglycosides?
Examples of aminoglycosides include gentamicin, tobramycin, amikacin, and streptomycin.

55. Are aminoglycosides usually bacteriostatic or bactericidal?
Aminoglycosides are generally bactericidal.

56. What organisms are aminoglycosides especially useful against?
Aminoglycosides are especially useful against serious gram-negative infections, including infections caused by Pseudomonas aeruginosa.

57. What are major toxicity concerns with aminoglycosides?
Major toxicity concerns with aminoglycosides include kidney toxicity and ototoxicity.

58. Why is inhaled tobramycin important in respiratory care?
Inhaled tobramycin is important because it is used in selected patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

59. What is the typical treatment cycle for inhaled tobramycin in cystic fibrosis?
Inhaled tobramycin is commonly given for 28 days on therapy followed by 28 days off therapy.

60. What instruction is important when administering TOBI by nebulizer?
No other medications should be mixed with TOBI in the nebulizer.

61. What is the TOBI Podhaler?
The TOBI Podhaler is a dry powder inhaler form of tobramycin used for inhalation therapy in cystic fibrosis patients.

62. What is Cayston?
Cayston is the brand name for inhaled aztreonam used to treat Pseudomonas aeruginosa in patients with cystic fibrosis.

63. What device is used to administer Cayston?
Cayston is administered with an approved Altera nebulizer system.

64. Why may a bronchodilator be given before inhaled aztreonam?
A fast-acting bronchodilator may be given before inhaled aztreonam to reduce the risk of bronchospasm.

65. What is colistin also known as?
Colistin is also known as polymyxin E.

66. When may inhaled colistin be used?
Inhaled colistin may be used for refractory gram-negative respiratory tract infections, especially when Pseudomonas aeruginosa is involved.

67. What are macrolides commonly used for in respiratory care?
Macrolides are commonly used for respiratory infections, including infections caused by atypical organisms.

68. What are examples of macrolides?
Examples of macrolides include erythromycin, clarithromycin, and azithromycin.

69. What ribosomal subunit do macrolides bind to?
Macrolides bind to the 50S ribosomal subunit.

70. What atypical organisms may be treated with macrolides?
Macrolides may be useful against Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

71. What are common adverse effects of macrolides?
Common adverse effects of macrolides include gastrointestinal effects and potential drug interactions.

72. What are examples of fluoroquinolones?
Examples of fluoroquinolones include ciprofloxacin, levofloxacin, and moxifloxacin.

73. How do fluoroquinolones work?
Fluoroquinolones inhibit bacterial nucleic acid function, interfering with DNA replication or related processes.

74. Which fluoroquinolones are commonly associated with respiratory infections?
Levofloxacin and moxifloxacin are respiratory fluoroquinolones commonly associated with pneumonia treatment.

75. What can reduce the absorption of fluoroquinolones?
Antacids and iron supplements can reduce the absorption of fluoroquinolones.

76. What are possible adverse effects of fluoroquinolones?
Possible adverse effects include nausea, vomiting, diarrhea, QT interval prolongation, seizures in susceptible patients, and drug interactions.

77. Why may renal dosing adjustments be needed for some antimicrobial agents?
Renal dosing adjustments may be needed because impaired kidney function can cause certain drugs to accumulate and increase toxicity risk.

78. What is vancomycin commonly used to treat?
Vancomycin is commonly used for serious gram-positive infections, including infections caused by methicillin-resistant Staphylococcus aureus.

79. What is linezolid?
Linezolid is an oxazolidinone antimicrobial agent that is active against important gram-positive bacteria.

80. What is trimethoprim-sulfamethoxazole commonly used for?
Trimethoprim-sulfamethoxazole is commonly used to treat Pneumocystis pneumonia and certain bacterial infections.

81. What is chloramphenicol?
Chloramphenicol is a broad-spectrum antimicrobial agent that is used less often because safer alternatives are usually available.

82. What major toxicity is associated with chloramphenicol?
Chloramphenicol is associated with bone marrow toxicity.

83. What organisms commonly cause acute community-acquired rhinosinusitis?
Common causes include Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and respiratory viruses.

84. Is acute bronchitis usually bacterial or viral?
Acute bronchitis is most often viral.

85. What organisms may be involved in exacerbations of chronic bronchitis?
Common organisms include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

86. What factors influence pneumonia treatment decisions?
Pneumonia treatment depends on whether the infection is community-acquired, hospital-acquired, ventilator-associated, aspiration-related, neutropenia-related, or associated with cystic fibrosis.

87. What agents may be used for community-acquired pneumonia?
Possible agents include macrolides, doxycycline, beta-lactams such as amoxicillin-clavulanate, and respiratory fluoroquinolones.

88. Why does severe community-acquired pneumonia often require combination therapy?
Combination therapy may be needed to cover common bacterial pathogens and atypical organisms such as Legionella.

89. What organism is especially important in hospital-acquired pneumonia?
Pseudomonas aeruginosa is especially important because it is a common nosocomial pathogen and may be resistant to multiple drugs.

90. What are examples of antipseudomonal agents?
Examples include cefepime, ceftazidime, piperacillin-tazobactam, and selected carbapenems other than ertapenem.

91. Why are local resistance patterns important in hospital-acquired infections?
Local resistance patterns help guide empiric therapy because the organisms and drug sensitivities can vary from one hospital or ICU to another.

92. What is ventilator-associated pneumonia?
Ventilator-associated pneumonia is pneumonia that develops in a patient receiving mechanical ventilation through an artificial airway.

93. What findings may suggest an infection-related ventilator-associated complication?
Findings may include worsening oxygenation, abnormal temperature, abnormal white blood cell count, and the start of a new antimicrobial agent continued for qualifying antimicrobial days.

94. Why can artificial airways increase infection risk?
Artificial airways bypass normal airway defenses and can provide surfaces for bacterial colonization and biofilm formation.

95. What are first-line medications commonly used for pulmonary tuberculosis?
First-line therapy commonly includes isoniazid, rifampin or another rifamycin, pyrazinamide, and ethambutol.

96. Why does tuberculosis require combination therapy?
Tuberculosis requires combination therapy because the organism is difficult to eradicate and resistance can develop if treatment is inadequate.

97. What adverse effect is associated with ethambutol?
Ethambutol may cause visual disturbances, including problems with visual acuity or color discrimination.

98. What are major antifungal drug classes?
Major antifungal classes include polyenes, azoles, echinocandins, and flucytosine.

99. What is amphotericin B?
Amphotericin B is a polyene antifungal agent that binds to fungal cell membranes and may be used for severe fungal infections.

100. Why is monitoring important during antimicrobial therapy?
Monitoring is important to evaluate clinical improvement, detect treatment failure, identify adverse effects, and determine whether therapy needs to be adjusted.

Final Thoughts

Antimicrobial agents are essential tools for preventing and treating infections, but they must be used with careful clinical judgment. The best approach is to match the agent to the suspected or identified organism, the infection site, the patient’s condition, and the available susceptibility data.

In respiratory care, these medications are especially important for pneumonia, cystic fibrosis infections, tuberculosis, fungal lung disease, influenza, RSV prevention, and infections in high-risk patients.

Effective use also requires respiratory assessment, infection prevention, proper aerosol delivery when needed, monitoring for toxicity, and adjusting therapy as new information becomes available.